Vor Bio price target lowered to $40 from $55 at Stifel

Stifel lowered the firm’s price target on Vor Bio (VOR) to $40 from $55 and keeps a Buy rating on the shares. The global Phase 3 UPSTREAM MG trial evaluating telitacicept in generalized Myasthenia Gravis continues to enroll patients across multiple regions and topline data is still anticipated in the first half of 2027, notes the analyst, whose reduced price target primarily reflects revised financing assumptions stemming from greater than $330M of equity capital raised in less than five months.